Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 37pembrolizumab 26cabozantinib 26Specimen Handling 23Magnetic Resonance Spectroscopy 21Ipilimumab 19lenvatinib 13belzutifan 13Axitinib 13CTLA-4 Antigen 10Sunitinib 9Radiosurgery 8Biopsy 8atezolizumab 7fludarabine 4avelumab 4aldesleukin 4Immunoglobulin G 4Disulfides 4zimberelimab 3toripalimab 3tivozanib 3pazopanib 3palbociclib 3durvalumab 3cemiplimab 3Surveys and Questionnaires 3Nephrectomy 3Everolimus 3Cyclophosphamide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Cell Count × 90 days × Clear all
NCT06318871 2026-05-11

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Dana-Farber Cancer Institute

Phase EARLY_PHASE1 Active not recruiting
5 enrolled
Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡